1Granstein RD. New treatments for psoriasis[J]. N Engl J Med, 2001, 345(4): 284-287.
2Bonifati C, Ameglio F. Cytokines in psoriasis[J]. Int J Dermatol, 1999, 38: 241-51.
3Woolacott N, Hawkins N, Masona A, et al. Etanercept and efal- izumab for the treatment of psoriasis: a systemic review [J]. Health Technology Assessment, 2006, 10(46): 1-233.
4De Groot M, Appelman M, Spuls P, et al. Initial experience with routine administration of etanereept in psoriasis [J]. Br J Dermatol, 2006, 155(4): 808-814.
同被引文献21
1Maeda S, Hayami Y, Naniwa T,et al. The Th17/IL23 axis and natu- ral immunity in psoriatic arthritis[ J]. Inter J Rheum,2012( 1 ) :1- 8.
2Wang M,Shen J, Jin H, et al. Recent progress in understanding mo- lecular mechanisms of cartilage degeneration dtlring osteoarthritis [J]. Ann N Y Acad Sci,2011,12(40) :61-69.
3Mease PJ. Spondyloarthritis: Is msthotrexate effective in psoriatic ar- thritis[J]. Nat Rev Rheumatol,2012,8(5) :251-252.
4Ghazizadeh R,Tosa M, Ghazizadeh M, Clinical improvement in pso- riasis with treatment of associated hyperlipidemia [ J ]. Am JM ed Sci ,2011,341 (5) :394-398.
